Table 1. Socio-demographic, clinical and treatment characteristics of CREW participants.
| Number of participants (%) | |
|---|---|
| N = 857 for socio-demographic & 852 for clinical / treatment details* | |
| Age (years) | |
| ≤ 50 | 55 (6.4) |
| 51–60 | 118 (13.8) |
| 61–70 | 311 (36.3) |
| 71–80 | 265 (30.9) |
| > 80 | 103 (12.0) |
| Unknown | 5 (0.6) |
| Mean (SD) [range] | 68.2 (10.7) [27–95] |
| Gender | |
| Male | 511 (59.6) |
| Female | 346 (40.4) |
| Ethnicity | |
| White | 662 (77.2) |
| Non-white | 25 (2.9) |
| Unknown | 170 (19.8) |
| Domestic status | |
| Married / living with partner | 534 (62.3) |
| Single / widowed / divorced / separated | 218 (25.4) |
| Unknown | 105 (12.3) |
| Employment status | |
| Employed | 202 (23.6) |
| Unemployed | 34 (4.0) |
| Retired | 513 (59.9) |
| Unknown | 108 (12.6) |
| Tumour site | |
| Colon | 550 (64.6) |
| Rectal | 302 (35.4) |
| Dukes stage | |
| A | 120 (14.1) |
| B | 452 (53.1) |
| C1 | 170 (19.9) |
| C2 | 99 (11.6) |
| Unknown–could not be determined + | 11 (1.3) |
| Stoma | |
| No | 550 (64.6) |
| Yes [Temporary: permanent: duration unknown] | 302 (35.4) [182: 92: 28] |
| Neo-adjuvant treatment | |
| No | 690 (81.0) |
| Yes [CT only: RT only: CT & RT] | 157 (18.4) [19: 68: 70] |
| Unknown | 5 (0.6) |
| Adjuvant treatment | |
| No | 556 (65.3) |
| Yes [CT only: RT only: CT & RT] | 296 (34.7) [278: 6: 12] |
| Biological therapy | |
| No | 702 (82.4) |
| Yes (Cetuximab/Avastin/Panitumumab/Other) | 84 (9.9) |
| Unknown | 66 (7.7) |
| Number of other long-term conditions ever had (reported in 3-month questionnaire) | |
| 0 | 183 (21.5) |
| 1 | 210 (24.6) |
| 2 | 148 (17.4) |
| ≥ 3 | 115 (13.5) |
| Unknown–not answered on questionnaire | 10 (1.2) |
| Unknown–no 3-month questionnaire | 186 (21.8) |
CT = chemotherapy; RT = radiotherapy
*Of the original 872 eligible participants who consented to follow-up, 15 withdrew at baseline prior to questionnaire data collection and five patients did not consent to collection of medical details
+ Dukes stage could not be determined for 11 participants with small tumours following neo-adjuvant therapy